Table 1 Top mergers and acquisitions with value over US$5 billion in 2014
From: Biopharma deal-making in 2014: a record year for M&A value
Month | Acquirer | Target | Deal value in US$ billions |
|---|---|---|---|
November | Actavis | Allergan | 66 |
February | Actavis | Forest Labatories | 28 |
April | Novartis | GlaxoSmithKline's oncology business | 16 (14.5 upfront and 1.5 in developmental milestones) |
May | Bayer | Merck & Co.'s consumer business | 14.2 |
December | Merck | Cubist Pharmaceuticals | 9.5 |
February | McKesson | Celesio | 8.5 |
August | Roche | InterMune | 8.3 |
April | GlaxoSmithKline | Novartis' vaccine business | 7.1 (5.25 upfront and 1.8 earnout) |
November | LabCorp | Covance | 6.1 |
July | Mylan | Abbott's branded generics for developed markets | 5.3 |
